Leflunomidă Arena

Leflunomide, the active ingredient in Leflunomidă Arena, is a disease-modifying antirheumatic drug (DMARD) presented as an oral formulation for systemic use. It is indicated for the treatment of inflammatory arthritis in adult patients. GNH USA supplies Leflunomidă Arena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomidă Arena is a DMARD that targets the immune pathways involved in chronic inflammatory arthritis.

Rheumatoid arthritis: reduces joint inflammation, pain, and slows structural damage progression. Psoriatic arthritis: alleviates joint swelling and skin lesions, improving functional ability. Adult patients with moderate to severe disease activity: helps achieve disease control when conventional therapy is insufficient.

Leflunomidă Arena may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and gastrointestinal upset. - Headache or dizziness. - Elevated blood pressure. - Hair thinning or loss. - Skin rash or itching.

Serious or Rare Side Effects: - Hepatotoxicity, including severe liver injury. - Life‑threatening infections due to immunosuppression. - Pulmonary toxicity such as interstitial lung disease. - Bone marrow suppression leading to anemia or leukopenia. - Severe cutaneous reactions (e.g., Stevens‑Johnson syndrome). - Teratogenic effects causing fetal malformation.

Before initiating therapy, clinicians should assess baseline laboratory values and patient risk factors.

Pregnancy contraindication: Leflunomide is teratogenic; avoid use in pregnant women and discontinue well before conception. Liver monitoring: Perform regular hepatic function tests during treatment. Blood pressure: Monitor and manage hypertension that may develop. Infection risk: Screen for latent infections and avoid live vaccines while on therapy. Store at room temperature below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Leflunomidă Arena can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Warfarin: increased bleeding risk. - Teriflunomide: additive hepatotoxicity. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): raise leflunomide levels.

Moderate Interactions (Monitor Closely): - Statins: heightened risk of myopathy. - Methotrexate: combined liver toxicity. - Antihypertensives (potassium‑sparing): potential hyperkalemia. - Oral contraceptives: reduced effectiveness, consider alternative contraception.